Volcano Corp (VOLC) 19.33 $VOLC
Volcano Corporation Schedules First Quarter Conference Call, Webcast
PR Newswire - Thu Apr 17, 7:00AM CDT
Volcano Corporation (Nasdaq:VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will report its operating results for the first quarter of fiscal 2014 on Friday, May 2.
Enrollment in Expansion Phase of Trials, Results and Initiation of Phase 2 Studies and Stock Movements - Analyst Notes on Pfizer, Cytokinetics, Portola Pharmaceuticals, Volcano, and Array BioPharma
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Cytokinetics, Incorporated (NASDAQ: CYTK), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), Volcano Corporation (NASDAQ: VOLC), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Clinical Trial Initiation, Executive Appointments, Priced Offering, FDA Clearance, and Upcoming Conferences - Analyst Notes on Cytokinetics, Quintiles, Kindred, Volcano, and Novadaq
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cytokinetics, Inc. (NASDAQ: CYTK), Quintiles Transnational Holdings, Inc. (NYSE: Q), Kindred Healthcare, Inc. (NYSE: KND), Volcano Corporation (NASDAQ: VOLC), and Novadaq Technologies Inc. (NASDAQ: NVDQ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Moving Average Crossover: Great News for Volcano (VOLC)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 5:46AM CDT
Moving Average Crossover: Great News for Volcano (VOLC)?
Volcano Corporation (VOLC) Crumbles: Stock Falls by 5.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 7:46AM CDT
Volcano Corporation (VOLC) saw a big move last session, breaking the recent trend of the company, as the stock is now trading below the volatile price range of $21.20 to $22.88 in the past one-month time frame.
Caliber Imaging & Diagnostics Appoints Joseph R. Williams as Its First Vice President of Global Marketing
GlobeNewswire - Wed Mar 26, 6:00AM CDT
Caliber Imaging & Diagnostics (OTCQB:LCDX), formerly Lucid, Inc., has appointed Joseph R. Williams as Vice President of Global Marketing, a newly created position, effective immediately.
Insider Trading Alert - CYN, WRE And VOLC Traded By Insiders
at The Street - Fri Mar 21, 9:30AM CDT
Stocks with insider trader activity include CYN, WRE and VOLC
FDA Clears Volcano Corp's iFR Modality - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 4:10PM CDT
Volcano Corporation recently received the U.S. FDA approval for the company's proprietary iFR (instant wave-Free Ratio) Modality.
Volcano Announces FDA Clearance of its Proprietary iFR® (instant wave-Free Ratio(TM)) Modality and Immediate Commencement of U.S. Limited Market Release
PR Newswire - Wed Mar 19, 7:00AM CDT
Volcano Corporation (NASDAQ: VOLC) a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced FDA clearance of its proprietary instant wave-Free Ratio(TM) or iFR® Modality.
Concise Analysis of the International Intravascular Ultrasound (IVUS) Market
M2 - Fri Mar 07, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/mgsk4v/intravascular) has announced the addition of the "Concise Analysis of the International Intravascular Ultrasound (IVUS) Market" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period of 2009 through 2018. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Intravascular Ultrasound (IVUS) in US$ Thousand by the following Product Segments: - Intravascular Ultrasound (IVUS) Catheters - Intravascular Ultrasound (IVUS) Consoles Company profiles are primarily based on public domain information including company URLs. The report profiles 10 companies including many key and niche players such as: - Boston Scientific Corp. - InfraReDx, Inc. - Silicon Valley Medical Instruments, Inc. - Terumo Corp. - Volcano Corp. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Market Trends & Growth Drivers 3. Issues And Challenges 4. Competitive Landscape 5. Clinical Studies 6. Product Overview 7. Coronary Stents Market - A Brief Overview 8. Product Approvals/Introductions 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 10 (including Divisions/Subsidiaries - 12) - The United States (7) - Japan (3) - Europe (2) - Germany (1) - Rest of Europe (1) For more information visit http://www.researchandmarkets.com/research/mg...ravascular
Volcano Corporation Presentation At Barclays Conference To Be Webcast
PR Newswire - Mon Mar 03, 7:00AM CST
Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the Barclays Global Healthcare Conference 2014 on Tuesday, March 11.
Global Optical Imaging Market Estimated to be Approximately Around $1.9 Billion by End of 2018, Growing at a CAGR of 11.37%
M2 - Thu Feb 27, 10:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/v44f8q/optical_imaging) has announced the addition of the "Optical Imaging Market (2013-2018) - Technology and Market Analysis Of Optical Coherence Tomography (OCT), Hyper Spectral Imaging (HSI), Near Infrared Spectroscopy (NIRS) And Photo- Acoustic Tomography (PAT) In Clinical Diagnostics & Research" report to their offering. The research service on "Advances in Optical Imaging (Medical Diagnostics & Clinical Research) - Technology Trends and Market Landscape Analysis" is an attempt to showcase the technology and market impact of existing and emerging optical imaging technologies having a huge growth potential in clinical medicine for the coming five years. This technology based research report categorizes optical imaging technologies based on applications, based on geography and on the basis of technicalities of various optical imaging modalities. Global optical imaging market can be estimated to be approximately around $1.9 billion by end of 2018, growing at a CAGR of 11.37%. Among the modalities, OCT occupies a major share contributing over 70% of the total optical imaging market. America is the major market for optical imaging equipments followed by Europe, and they have been driving the market significantly owing to the growth of aging population across the developed economies. Other than the mature markets, emerging economies such as Asia-pacific and Middle-East are the future drivers of optical imaging market. This report is further divided into segments and sub-segments providing exhaustive market analysis with respect to each technology from the years 2010 and 2011, as well as forecast up to 2018. Each technology is comprehensively analyzed at a granular level by geography (North America, EU, Asia and rest of the world) to provide in-depth information on the global scenario. Investment opportunity evaluation and emerging initial public offerings (IPOs) can be assessed within the optical imaging sector. Strategic recommendations for technology developers are elaborately discussed in this research service. Challenges: - Inadequate clinical data validation for optical methods restricts adoption. - Lack of reimbursement facilities. Companies Mentioned: - Ase Optics - Bioptigen, Inc. - Topcon Medical Systems, Inc. - Carl Zeiss Meditec - Chemimage Corporation - Cytoviva, Inc. - Headwall Photonics, Inc. - Heidelberg Engineering - Michelson Diagnostics Ltd ( Vivosight) - Raytheon Elcan Optical Technologies - Somanetics Corporation - St. Jude Medical - Volcano Corporation For more information visit http://www.researchandmarkets.com/research/v4...al_imaging About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Wider Q4 Loss, Poor Outlook at Volcano Corp. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 8:00AM CST
Volcano Corporation reported adjusted net loss of 29 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate loss of 24 cents per share.
Volcano Reports Fourth Quarter Revenues Increase Six Percent On A Constant Currency Basis
PR Newswire - Mon Feb 24, 3:05PM CST
Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today reported results for the fourth quarter and all of 2013.
Epizyme Announces Exercise of Underwriters' Option to Purchase Additional Shares of Common Stock
PR Newswire - Tue Feb 11, 7:00AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company that is discovering, developing and planning to commercialize innovative personalized therapeutics for patients with genetically defined cancers, today announced that, following the initial closing of its recent public offering on February 10, 2014, the underwriters for the offering exercised in full their option to purchase 673,901 additional shares of common stock from the Company at the public offering price of $29.25 per share, less underwriting discounts. The sale of the additional shares is expected to close on or about February 12, 2014, subject to customary closing conditions.
Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
PR Newswire - Tue Feb 04, 7:00AM CST
Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will report its operating results for the fourth quarter of fiscal 2013 on Monday, February 24.
Axsun Technologies Announces Volume Purchase Order for Swept Laser Engines from Michelson Diagnostics Ltd.
PR Newswire - Mon Feb 03, 9:44AM CST
Axsun Technologies, Inc., a wholly-owned subsidiary of Volcano Corporation (NASDAQ: VOLC) and a leading developer and manufacturer of advanced photonic components and subsystems, has received a volume purchase order for Swept Laser OCT Engines from Michelson Diagnostics Ltd. The Axsun Swept Laser OCT Engine will power the new Michelson Diagnostics' Vivosight Multi-Beam OCT system. The Vivosight Multi-Beam OCT system is the first OCT scanner to receive FDA 510(k) clearance for imaging skin in high definition, revealing subsurface tissue structure at unprecedented detail.
Axsun Technologies Announces Qualification of New Lead-Free Tunable Laser Platform at the 2014 BIOS/Photonics West Exhibition
PR Newswire - Thu Jan 30, 7:30AM CST
Axsun Technologies Inc., a wholly-owned subsidiary of Volcano Corporation (NASDAQ: VOLC) and a leading developer and manufacturer of advanced photonic components and subsystems, has announced the Qualification of their new Lead-Free Tunable Laser packaging platform. Axsun's new Lead-Free platform provides the same performance and reliability as previous generations and meets the requirements of the Reduction of Hazardous Substances (ROHS) Directive 2011/65/EU (also known as ROHS2). This new directive eliminates exemptions for several product categories, including Medical Devices that were present in the 2002 Directive. Axsun will begin sampling new Lead-Free Engines in May 2014.
Downgrade Alert for Volcano (VOLC)
Comtex SmarTrend(R) - Tue Jan 21, 8:04AM CST
Volcano (NASDAQ:VOLC) was downgraded from Outperform to Market Perform at Raymond James today. The stock closed yesterday at $21.00 on volume of 753,000 shares, above average daily volume of 724,000. Volcano share prices have moved between a 52-week high of $26.23 and a 52-week low of $16.37 and closed yesterday at 28% above that low price at $21.00 per share. In the last five trading sessions, the 50-day moving average (MA) has climbed 0.7% while the 200-day MA has remained constant.
Volcano Corporation Schedules First Quarter Conference Call, Webcast
PR Newswire - Thu Apr 17, 7:00AM CDT
Volcano Corporation (Nasdaq:VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will report its operating results for the first quarter of fiscal 2014 on Friday, May 2.
Enrollment in Expansion Phase of Trials, Results and Initiation of Phase 2 Studies and Stock Movements - Analyst Notes on Pfizer, Cytokinetics, Portola Pharmaceuticals, Volcano, and Array BioPharma
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Cytokinetics, Incorporated (NASDAQ: CYTK), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), Volcano Corporation (NASDAQ: VOLC), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Clinical Trial Initiation, Executive Appointments, Priced Offering, FDA Clearance, and Upcoming Conferences - Analyst Notes on Cytokinetics, Quintiles, Kindred, Volcano, and Novadaq
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cytokinetics, Inc. (NASDAQ: CYTK), Quintiles Transnational Holdings, Inc. (NYSE: Q), Kindred Healthcare, Inc. (NYSE: KND), Volcano Corporation (NASDAQ: VOLC), and Novadaq Technologies Inc. (NASDAQ: NVDQ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Moving Average Crossover: Great News for Volcano (VOLC)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 5:46AM CDT
Moving Average Crossover: Great News for Volcano (VOLC)?
Volcano Corporation (VOLC) Crumbles: Stock Falls by 5.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 7:46AM CDT
Volcano Corporation (VOLC) saw a big move last session, breaking the recent trend of the company, as the stock is now trading below the volatile price range of $21.20 to $22.88 in the past one-month time frame.
Caliber Imaging & Diagnostics Appoints Joseph R. Williams as Its First Vice President of Global Marketing
GlobeNewswire - Wed Mar 26, 6:00AM CDT
Caliber Imaging & Diagnostics (OTCQB:LCDX), formerly Lucid, Inc., has appointed Joseph R. Williams as Vice President of Global Marketing, a newly created position, effective immediately.
Insider Trading Alert - CYN, WRE And VOLC Traded By Insiders
at The Street - Fri Mar 21, 9:30AM CDT
Stocks with insider trader activity include CYN, WRE and VOLC
FDA Clears Volcano Corp's iFR Modality - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 4:10PM CDT
Volcano Corporation recently received the U.S. FDA approval for the company's proprietary iFR (instant wave-Free Ratio) Modality.
Volcano Announces FDA Clearance of its Proprietary iFR® (instant wave-Free Ratio(TM)) Modality and Immediate Commencement of U.S. Limited Market Release
PR Newswire - Wed Mar 19, 7:00AM CDT
Volcano Corporation (NASDAQ: VOLC) a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced FDA clearance of its proprietary instant wave-Free Ratio(TM) or iFR® Modality.
Concise Analysis of the International Intravascular Ultrasound (IVUS) Market
M2 - Fri Mar 07, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/mgsk4v/intravascular) has announced the addition of the "Concise Analysis of the International Intravascular Ultrasound (IVUS) Market" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period of 2009 through 2018. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Intravascular Ultrasound (IVUS) in US$ Thousand by the following Product Segments: - Intravascular Ultrasound (IVUS) Catheters - Intravascular Ultrasound (IVUS) Consoles Company profiles are primarily based on public domain information including company URLs. The report profiles 10 companies including many key and niche players such as: - Boston Scientific Corp. - InfraReDx, Inc. - Silicon Valley Medical Instruments, Inc. - Terumo Corp. - Volcano Corp. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Market Trends & Growth Drivers 3. Issues And Challenges 4. Competitive Landscape 5. Clinical Studies 6. Product Overview 7. Coronary Stents Market - A Brief Overview 8. Product Approvals/Introductions 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 10 (including Divisions/Subsidiaries - 12) - The United States (7) - Japan (3) - Europe (2) - Germany (1) - Rest of Europe (1) For more information visit http://www.researchandmarkets.com/research/mg...ravascular
Volcano Corporation Presentation At Barclays Conference To Be Webcast
PR Newswire - Mon Mar 03, 7:00AM CST
Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the Barclays Global Healthcare Conference 2014 on Tuesday, March 11.
Global Optical Imaging Market Estimated to be Approximately Around $1.9 Billion by End of 2018, Growing at a CAGR of 11.37%
M2 - Thu Feb 27, 10:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/v44f8q/optical_imaging) has announced the addition of the "Optical Imaging Market (2013-2018) - Technology and Market Analysis Of Optical Coherence Tomography (OCT), Hyper Spectral Imaging (HSI), Near Infrared Spectroscopy (NIRS) And Photo- Acoustic Tomography (PAT) In Clinical Diagnostics & Research" report to their offering. The research service on "Advances in Optical Imaging (Medical Diagnostics & Clinical Research) - Technology Trends and Market Landscape Analysis" is an attempt to showcase the technology and market impact of existing and emerging optical imaging technologies having a huge growth potential in clinical medicine for the coming five years. This technology based research report categorizes optical imaging technologies based on applications, based on geography and on the basis of technicalities of various optical imaging modalities. Global optical imaging market can be estimated to be approximately around $1.9 billion by end of 2018, growing at a CAGR of 11.37%. Among the modalities, OCT occupies a major share contributing over 70% of the total optical imaging market. America is the major market for optical imaging equipments followed by Europe, and they have been driving the market significantly owing to the growth of aging population across the developed economies. Other than the mature markets, emerging economies such as Asia-pacific and Middle-East are the future drivers of optical imaging market. This report is further divided into segments and sub-segments providing exhaustive market analysis with respect to each technology from the years 2010 and 2011, as well as forecast up to 2018. Each technology is comprehensively analyzed at a granular level by geography (North America, EU, Asia and rest of the world) to provide in-depth information on the global scenario. Investment opportunity evaluation and emerging initial public offerings (IPOs) can be assessed within the optical imaging sector. Strategic recommendations for technology developers are elaborately discussed in this research service. Challenges: - Inadequate clinical data validation for optical methods restricts adoption. - Lack of reimbursement facilities. Companies Mentioned: - Ase Optics - Bioptigen, Inc. - Topcon Medical Systems, Inc. - Carl Zeiss Meditec - Chemimage Corporation - Cytoviva, Inc. - Headwall Photonics, Inc. - Heidelberg Engineering - Michelson Diagnostics Ltd ( Vivosight) - Raytheon Elcan Optical Technologies - Somanetics Corporation - St. Jude Medical - Volcano Corporation For more information visit http://www.researchandmarkets.com/research/v4...al_imaging About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Wider Q4 Loss, Poor Outlook at Volcano Corp. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 8:00AM CST
Volcano Corporation reported adjusted net loss of 29 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate loss of 24 cents per share.
Volcano Reports Fourth Quarter Revenues Increase Six Percent On A Constant Currency Basis
PR Newswire - Mon Feb 24, 3:05PM CST
Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today reported results for the fourth quarter and all of 2013.
Epizyme Announces Exercise of Underwriters' Option to Purchase Additional Shares of Common Stock
PR Newswire - Tue Feb 11, 7:00AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company that is discovering, developing and planning to commercialize innovative personalized therapeutics for patients with genetically defined cancers, today announced that, following the initial closing of its recent public offering on February 10, 2014, the underwriters for the offering exercised in full their option to purchase 673,901 additional shares of common stock from the Company at the public offering price of $29.25 per share, less underwriting discounts. The sale of the additional shares is expected to close on or about February 12, 2014, subject to customary closing conditions.
Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
PR Newswire - Tue Feb 04, 7:00AM CST
Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will report its operating results for the fourth quarter of fiscal 2013 on Monday, February 24.
Axsun Technologies Announces Volume Purchase Order for Swept Laser Engines from Michelson Diagnostics Ltd.
PR Newswire - Mon Feb 03, 9:44AM CST
Axsun Technologies, Inc., a wholly-owned subsidiary of Volcano Corporation (NASDAQ: VOLC) and a leading developer and manufacturer of advanced photonic components and subsystems, has received a volume purchase order for Swept Laser OCT Engines from Michelson Diagnostics Ltd. The Axsun Swept Laser OCT Engine will power the new Michelson Diagnostics' Vivosight Multi-Beam OCT system. The Vivosight Multi-Beam OCT system is the first OCT scanner to receive FDA 510(k) clearance for imaging skin in high definition, revealing subsurface tissue structure at unprecedented detail.
Axsun Technologies Announces Qualification of New Lead-Free Tunable Laser Platform at the 2014 BIOS/Photonics West Exhibition
PR Newswire - Thu Jan 30, 7:30AM CST
Axsun Technologies Inc., a wholly-owned subsidiary of Volcano Corporation (NASDAQ: VOLC) and a leading developer and manufacturer of advanced photonic components and subsystems, has announced the Qualification of their new Lead-Free Tunable Laser packaging platform. Axsun's new Lead-Free platform provides the same performance and reliability as previous generations and meets the requirements of the Reduction of Hazardous Substances (ROHS) Directive 2011/65/EU (also known as ROHS2). This new directive eliminates exemptions for several product categories, including Medical Devices that were present in the 2002 Directive. Axsun will begin sampling new Lead-Free Engines in May 2014.
Downgrade Alert for Volcano (VOLC)
Comtex SmarTrend(R) - Tue Jan 21, 8:04AM CST
Volcano (NASDAQ:VOLC) was downgraded from Outperform to Market Perform at Raymond James today. The stock closed yesterday at $21.00 on volume of 753,000 shares, above average daily volume of 724,000. Volcano share prices have moved between a 52-week high of $26.23 and a 52-week low of $16.37 and closed yesterday at 28% above that low price at $21.00 per share. In the last five trading sessions, the 50-day moving average (MA) has climbed 0.7% while the 200-day MA has remained constant.
